Recently, Scindy Pharmaceutical (Suzhou) Co., Ltd. (hereinafter referred to as "Scindy Pharmaceutical") and Shanghai Yanyin Technology Co., Ltd. (hereinafter referred to as "Yanyin Technology") reached a strategic cooperation agreement, jointly opening a new chapter of innovative development. Both parties will fully utilize their respective technological advantages and industry resources to promote the application of advanced LNP carrier technology in the field of synthetic biology.

Scindy Pharmaceutical is committed to providing impetus for basic research and clinical translation of innovative synthetic biology technologies such as RNA therapy through advanced nano delivery technology. The full chain LNP delivery technology solution (TLS) driven by artificial intelligence and rational evidence from Scindy Pharmaceutical, combined with Yan Yin Technology's AI big model and digital platform, will greatly improve the efficiency and quality of RNA drug research and development, and accelerate the expansion of new application areas.

Chen Xiaobao, founder and general manager of Scindy Pharmaceutical, said, "We are pleased to have reached a strategic cooperation with Yanyin Technology. Yanyin Technology has technological and market advantages in the digitalization of biomedicine, and Scindy Pharmaceutical has underlying technological advantages and product development experience in the LNP carrier field. Our newly launched NeoLNP ? The series of cell and in vivo transfection kits fully utilize the high delivery efficiency and safety advantages of LNP, greatly improving the development efficiency of RNA drugs. The cooperation between both parties will exert a synergistic effect, improve the efficiency and quality of drug research and development, and contribute to the research and industrialization of Chinese drugs. This collaboration will also promote the expansion of innovative LNP carriers into new fields such as synthetic biology, opening up new possibilities for future research and applications.

Dr. Chen Zeping, founder and CEO of Yanyin Technology, said, "Thank you to Scindy Pharmaceutical for recognizing us. Scindy Pharmaceutical has made great contributions to the biopharmaceutical industry with its profound professional knowledge and innovative capabilities in RNA therapy. Yanyin Zhiyan Cloud, as a digital research collaboration platform focused on biopharmaceuticals, helps the biopharmaceutical research and development process transform from traditional inefficient paper-based management to digital efficient management. Through this cooperation, Yanyin Technology and Scindy Pharmaceutical will be able to complement each other's resources and accelerate technological innovation. We believe that through the strong alliance between Scindy Pharmaceutical and Yanyin Technology, it will bring revolutionary innovation power to the biopharmaceutical industry and jointly embrace the bright future of the biopharmaceutical field.

Scindy Pharmaceutical focuses on promoting basic research and clinical translation of innovative synthetic biology technologies, including RNA therapy, with independent innovation in nanocarrier technology as its core. The company has established a full chain LNP delivery technology solution (TLS) driven by artificial intelligence and rational empirical evidence, with a core lipid material library, LNP kit, and RNA sequence design model. It has successfully developed i-Core LNP represented by lung nebulization inhalation and local skin administration ? Extrahepatic targeted RNA delivery protocol. The company launches NeoLNP for basic research and early development ? A series of products have been transfected into cells and animals, and breakthroughs have been made in the delivery of LNP in immune cells and stem cells, serving the basic life science and translational research with advanced delivery technology.

Yanyin Technology focuses on providing artificial intelligence research collaboration platforms and solutions for the biopharmaceutical field, including molecular biology gene editing research platforms, biopharmaceutical large model libraries, laboratory process automation systems, data intelligent management, intelligent analysis and prediction, and visualization software. It provides artificial intelligence research services to major universities, research institutions, and pharmaceutical companies across the country, helping researchers in the biopharmaceutical industry conduct research experiments and data analysis more efficiently, and improving the efficiency and quality of scientific research.